Pharmacokinetics
Given the promising results from in vitro and in vivo studies, these three highly selective CDK4/6 inhibitors were further investigated for pharmacokinetics, efficacy, and safety in clinical trials. Reported clinical trials on palbociclib, ribociclib, and abemaciclib in breast cancer are listed in Table
1.
Table 1
Reported clinical trials with targeted CDK4/6 inhibitors in breast cancer
Palbociclib |
RB+ ABC
N = 5 | I | Administrated in six dose escalation cohorts (standard 3 + 3 design) MTD and RP2D: 125 mg | SD: 20% (1/5) | NCT 00141297 | |
ER+/HER2- ABC
N = 9 | I | MTD: 125 mg; Palbociclib (125 mg QD, 3 weeks on/1 week off) plus letrozole (2.5 mg, continuous) | PR: 33% (2/6) SD: 33% (2/6) | NCT 01684215 | |
ER+/HER2-ABC
N = 165 | II | Palbociclib (125 mg QD, 3 weeks on/1 week off) plus letrozole (2.5 mg, continuous) | PFS: 20.2 months for the palbociclib plus letrozole group and 10.2 months for the letrozole group (HR 0.488, 95%CI 0.319-0.748; one-sided
p = 0.0004) | NCT 00721409 | |
RB+ MBC
N = 37 | II | Palbociclib (125 mg QD, 3 weeks on/1 week off) | PR: 7% (2/28) SD: 50% (14/28) PFS: 3.8 months (1.9–5.8) for HR+/HER2- patients, 5.1 months (5.1–∞)for HR+/HER2+ patients, 1.5 months (0.62-∞) for HR-/HER2- patients, 4.5 months for HR+ patients, and 1.5 months for HR- patients | NCT 01037790 | |
HR+/HER2-ABC
N = 521 | III | Palbociclib (125 mg QD, 3 weeks on/1 week off) plus fulvestrant (500 mg IM every 2 weeks For the first three injections and then every 4 weeks), or matching placebo plus fulvestrant | PFS: 9.2 months (95%CI, 7.5 to ∞) for palbociclib plus fulvestrant group and 3.8 months (95%CI, 3.5 to 5.5) for placebo plus fulvestrant group (HR: 0.42; 95%CI,0.32 to 0.56; P < 0.001) | NCT 01942135 | |
ER+/HER2-ABC
N = 666 | III | Palbociclib (125 mg QD, 3 weeks on/1 week off) plus letrozole (2.5 mg, continuous) | PFS: 24.8 months for the palbociclib plus letrozole group and 14.5 months for the letrozole group (HR 0.488, 95%CI 0.319-0.748; one-sided p = 0.0004) | NCT 01740427 | |
Ribociclib |
RB+ ABC
N = 20 | I | MTD: 900 mg QD for 3 weeks on/1 week off RDE: 600 mg QD For 3 weeks on/1 week off; Ribociclib: 600 mg QD 3 weeks on/1 week off or continuous | PR: 1 (1/20) (600 mg/day continuous) | NCT 01237236 | |
HR+/HER2- RBC or MBC
N = 668 | III | Ribociclib (600 mg QD 3 weeks on/1 week off) plus letrozole (2.5 mg QD) or matching placeboplus letrozole. | PFS: ribociclib group versus placebo group (0.56;95%CI, 0.43to 0.72, p < 0.001); ribociclib group versus placebo group (63.0% (95%CI, 54.6 to 70.3) and 42.2% (95%CI,34.8 to 49.5) after 18 months, OR: ribociclib Group versus placebo group (52.7% and 37.1%) | NCT 01958021 | |
Abemaciclib |
BC
N = 66 | I | Abemaciclib (200 mg Q12H continuous for 4 weeks) | PR: 31% in HR+ patients and none in HR- patients SD: 50% in HR+ patients and 33% in HR- patients | NCT 01394016 | |
ER-/PR-/HER2 + BC
N = 1 | I | Abemaciclib (200 mg Q12H continuous for 4 weeks) | Tumor size decreases more than 30% from baseline | NCT 02014129 | |
Palboliclib is slowly absorbed and eliminated in cancer patients after orally administrated [
82‐
84]. The phase I clinical study in Japanese patients with solid tumors was conducted to assess the pharmacokinetics of palbociclib in patients with solid tumors [
83]. Its half-life was 23–26 h and there were no drug to drug interactions between letrozole and palbociclib in this study [
83]. Besides, 125 mg once daily over 3 weeks on followed by 1 week off schedule was the maximum tolerated dose (MTD) and was recommended for both monotherapy and combination strategy in ER-positive/HER2-negative advanced breast cancer [
83]. Another two phase I studies both enrolling different RB-positive solid tumor patients indicated that palbociclib was slowly absorbed with median time from oral dose to maximum plasma concentration (
T
max) 4.2 or 5.5 h and slowly eliminated with mean half-life 26.7 or 25.9 h, respectively [
82,
84].
According to results of the phase II clinical trial conducted by Infante JR, MTD and recommended dose for expansion (RDE) of ribociclib were 900 and 600 mg daily of 3 weeks on and 1 week off over a 28-day schedule, respectively, based on the assessment on the safety and efficacy of the dose-escalation schedules [
85]. Upon oral administration, ribociclib was absorbed with median
T
max varying from 1 to 5 h [
85]. The half-life of ribociclib was approximately 36 h [
86] and the average effective half-life was approximately 32 h at the dose of 600 mg daily of 3/1 schedule [
85]. During 17 days following oral dosing, plasma concentrations rapidly increased about two- to threefolds because of accumulation [
85]. The level of LEQ803, the main active metabolite of ribociclib, was positively linked to the dose of the parent drug ribociclib [
85].
Abemaciclib is absorbed slowly ranging from 4 to 6 h from oral dose to maximum plasma concentration [
75]. Abemaciclib was widely eliminated and distributed, and the average terminal elimination half-life varied from 17.4 to 38.1 h without significant dose-dependent clearance [
75]. The mean top of plasma concentration of patients with 150 and 200 mg twice daily treatment reached 249 and 298 ng/mL, respectively [
75]. Also, the cerebrospinal fluid concentration of abemaciclib ranged from 2.2 to 14.7 nmol/L, which was beyond the dissociation constant of CDK4/cyclin D1 combination and was close to the unbound plasma concentrations [
75].
Single-agent strategies
According to the phase II clinical study on palbociclib monotherapy enrolling RB-positive advanced breast cancer patients including 31 patients with hormone receptor (HR)-positive/HER2-negative disease, 2 patients with HR-positive/HER2-positive disease, and 4 patients with HR-negative/HER2-negative disease, clinical benefit (CB) was noted in 7 individuals overall, all of which were HR-positive patients after the treatment of palbociclib at the recommonded dose 125 mg daily on the 3/1 schedule [
87]. The median PFS of the HR-positive group versus HR-negative population was 4.5 and 1.5 months (
P = 0.03), indicating ER-positive breast tumors were more responsive to palbociclib treatment than ER-negative disease [
87]. Furthermore, the degree of previous endocrine therapy impacted the efficacy of palbociclib in breast cancer [
87]. HR-positive patients who had received more than two lines of anti-hormone regimens enjoyed 3 months longer median PFS than patients who had received less than two lines of these regimens after palbociclib treatment [
87]. However, prior therapy of cytotoxic drugs did not significantly affect the median PFS on palbociclib treatment [
87].
A phase I dose-escalation clinical study on ribociclib for single-agent therapy, enrolling 132 Rb-positive solid tumors including 20 breast cancer cases, demonstrated that one breast cancer patient with positive status of CCND1 and ER achieved partial responses (PR) at the dose of 600 mg daily during continuous ribociclib treatment [
85].
A phase I study was conducted by Patnaik A to assess the pharmacokinetic profile, efficacy, and safety of abemaciclib in cancer patients. In this study, a total of 225 patients were enrolled including breast cancer patients [
75]. The efficacy of abemaciclib monotherapy was investigated in 47 breast cancer patients including the following three subtypes: HR-positive/HER2-positive (
N = 11), HR-positive/HER2-negative (
N = 25), and HR-negative (
N = 9) [
75]. The overall level of complete response (CR) plus PR plus stable disease (SD) was much higher in HR-positive population than HR-negative subgroup (80 versus 33%) [
75]. About 31% achieved PR and 50% achieved SD among 36 HR-positive patients, while none had PR and 33% had SD in nine HR-negative individuals [
75]. Furthermore, abemaciclib treatment improved median PFS to greater extent in HR-positive breast cancer patients (8.8 months) than in HR-negative patients (1.1 months) [
75]. However, the HER2 status did not make significant difference in the effects of abemaciclib on PFS of HR-positive breast cancer population (7.2 versus 8.8 months) [
75]. These data indicated that abemaciclib was highly effective in HR-positive breast cancer for single-agent therapy. In order to further investigate the efficacy and safety of abemaciclib monotherapy, a phase II study was conducted, which included 132 female patients bearing HR-positive/HER2-negative advanced or metastatic breast cancer with disease progression during both hormone therapy and 1 or 2 lines of chemotherapy [
86]. Patients received abemaciclib treatment at the dose of 200 mg twice daily continuously. Of patients evaluable for response, the clinical benefit rate including CR, PR, and SD reached 42.4%, and the median PFS was 6 months [
86].
Safety profile
The management of drug-related adverse events is a pivotal aspect of treatment. Reported clinical adverse events caused by palbociclib include neutropenia, leucopenia, fatigue, pulmonary embolism, back pain, and diarrhea. Among these, neutropeniais the primary toxicity of palbociclib [
82‐
84,
87,
88,
92]. Previous study conducted by Flaherty KT enrolled 41 patients with distinct RB-positive solid tumors including melanoma, breast and other types, demonstrated that neutropenia is the only dose-limiting event and the most common non-hematologic adverse effects included fatigue, nausea, and diarrhea [
84]. According to the phase 2 study by Finn RS, grades 3–4 neutropenia was noted in about half of advanced breast cancer patients treated with palbociclib plus letrozole, while in only 1% of patients treated with letrozole alone [
88]. For leucopenia and fatigue, it was 19% versus none and four (4%) versus one (1%), respectively [
88]. Furthermore, serious adverse events such as back pain, pulmonary embolism and diarrhea occurred in 2, 4, and 2% of palbociclib plus letrozole group, respectively [
88]. But, febrile neutropenia or neutropenia-related infections were not observed among these patients during this study [
88]. Also, according to the phase 3 study of 521 women with ER-positive/HER2-negative advanced or metastatic breast cancer, the adverse events were most commonly observed in palbociclib plus fulvetrant group in comparison with the placebo plus fulcestrant group, including neutropenia (62.0 versus 0.6%), leukopenia (25.2 versus 0.6%), anemia (2.6 versus 1.7%), thrombocytopenia (2.3 versus 0%), and fatigue (2.0 versus 1.2%) [
90].
The safety of ribociclib was also assessed in clinical trials. According to the phase 3 clinical trial by Hortobagyi GN, common grade 3 or 4 adverse events were neutropenia (59.3% in the ribociclib group and 0.9% in the placebo group) and leukopenia (21.0 versus 0.6%) [
91]. Infante JR reported that neutropenia and thrombocytopenia were the most common dose limiting toxicities (DLT) according to the MTD determination on seventy patients after cycle 1 treatment [
85]. The most common hematologic adverse events were treatment-related neutropenia, leukopenia, thrombocytopenia and anemia, and the most common non-hematologic treatment-related adverse events were fatigue, nausea, and vomiting for all grades [
85]. Approximately 9% of patients treated at 600 mg daily of 3 weeks on followed by 1 week off schedule experienced treatment-related asymptomatic QTcF prolongation, but grade 3/4 asymptomatic QTcF prolongation only occurred at the dose of more than 900 mg daily [
85]. It was reversible and parallel with the maximal plasma concentration kinetics [
85].
Abemaciclib treatment represents a distinct toxicity profile. In contrast to palbociclib and ribociclib, the DLT of abemaciclib was fatigue and this agent produced relatively less neutropenia might be due to the higher specific selectivity of this agent for CDK4 than for CDK6 [
86]. The clinical study of a total of 225 patients with multiple cancer types showed that abemaciclib treatment related adverse events of all grades included diarrhea, nausea, fatigue, vomiting, leukopenia, thrombocytopenia, neutropenia, anemia, anorexia, increased creatinine, and weight loss [
75]. The most common adverse events caused by abemaciclib treatment included fatigue and the gastrointestinal, renal and hematopoietic systems [
75]. Grade 3 fatigue was DLT and the MTD was 200 mg every 12 h [
75]. At 200 mg twice daily, one out of seven patients experienced DLT of grade 3 fatigue, and 275 mg twice daily endowed two out of three patients with the DLT of grade 3 fatigue [
75]. According to a phase 1 clinical trial of 12 cancer patients demonstrated that diarrhea was the most common treatment–emergent adverse event and it could be managed to have no effects on the continuation of abemaciclib treatment at the dose of 200 mg twice daily [
93].